| BRIDGEBIO PHARMA DL-,001 |
| USA |
| Gesundheit |
| US10806X1028 / A2PLX7 |
| 2CL (Frankfurt) / BBIO (NASDAQ) |
| FRA:2CL, ETR:2CL, 2CL:GR, NASDAQ:BBIO |
| - |
| https://bridgebio.com/ |
|
BridgeBio Pharma, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for patients with genetic diseases and genetically driven cancers. The company concentrates on conditions with well-defined genetic causes,..
>Volltext.. |
| 13351.17 Mio. EUR |
| 15481.97 Mio. EUR |
| 508.47 Mio. EUR |
| -437.39 Mio. EUR |
| -632.61 Mio. EUR |
| -3.28 EUR |
| 2967.66 Mio. EUR |
| 771.92 Mio. EUR |
| -389.23 Mio. EUR |
| 1.15 |
| 326.21% |
| -1.15% |
| - |
| - |
| - |
| 2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 7.970.477 Euro. |
| BRIDGEBIO |
| 09.07.26 |